Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Safety and dose modification for patients receiving niraparib

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Research output: Contribution to journalConference articleResearchpeer-review

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Human endogenous retroviruses and their implication for immunotherapeutics of cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cancer of the corpus uteri

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities

    Research output: Contribution to journalReviewResearchpeer-review

  4. Major clinical research advances in gynecologic cancer in 2017

    Research output: Contribution to journalReviewResearchpeer-review

  • J S Berek
  • U A Matulonis
  • U Peen
  • P Ghatage
  • S Mahner
  • A Redondo
  • A Lesoin
  • N Colombo
  • I Vergote
  • O Rosengarten
  • J Ledermann
  • M Pineda
  • S Ellard
  • J Sehouli
  • A Gonzalez-Martin
  • D Berton-Rigaud
  • R Madry
  • A Reinthaller
  • S Hazard
  • W Guo
  • M R Mirza
View graph of relations

Background: Niraparib is a poly(ADP-ribose) polymerase inhibitor approved in the USA and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In the pivotal ENGOT-OV16/NOVA trial, the dose reduction rate due to treatment-emergent adverse event (TEAE) was 68.9%, and the discontinuation rate due to TEAE was 14.7%, including 3.3% due to thrombocytopenia. A retrospective analysis was carried out to identify clinical parameters that predict dose reductions.

Patients and methods: All analyses were carried out on the safety population, comprising all patients who received at least one dose of study drug. Patients were analyzed according to the study drug consumed (i.e., as treated). A predictive modeling method (decision trees) was used to identify important variables for predicting the likelihood of developing grade ≥3 thrombocytopenia within 30 days after the first dose of niraparib and determine cut-off points for chosen variables.

Results: Following dose modification, 200 mg was the most commonly administered dose in the ENGOT-OV16/NOVA trial. Baseline platelet count and baseline body weight were identified as risk factors for increased incidence of grade ≥3 thrombocytopenia. Patients with a baseline body weight <77 kg or a baseline platelet count <150 000/µl in effect received an average daily dose ∼200 mg (median = 207 mg) due to dose interruption and reduction. Progression-free survival in patients who were dose reduced to either 200 or 100 mg was consistent with that of patients who remained at the 300 mg starting dose.

Conclusions: The analysis presented suggests that patients with baseline body weight of <77 kg or baseline platelets of <150 000/µl may benefit from a starting dose of 200 mg/day.

ClinicalTrials.gov ID: NCT01847274.

Original languageEnglish
JournalAnnals of Oncology
Volume29
Issue number8
Pages (from-to)1784-1792
Number of pages9
ISSN0923-7534
DOIs
Publication statusPublished - 1 Aug 2018

ID: 55906596